Wnt/β-catenin signaling is a therapeutic target in anaplastic thyroid carcinoma

Diana Diaz,Kensey Bergdorf,Matthew A. Loberg,Courtney J. Phifer,George J. Xu,Quanhu Sheng,Sheau-Chiann Chen,Jamal M. Byrant,Megan L. Tigue,Heather Hartmann,Sarah L. Rohde,James L. Netterville,Naira Baregamian,Jeremy A. Goettel,Fei Ye,Ethan Lee,Vivian L. Weiss
DOI: https://doi.org/10.1007/s12020-024-03887-0
2024-05-30
Endocrine
Abstract:Anaplastic thyroid carcinoma (ATC) is a highly aggressive malignancy that has consistently shown Wnt/β-catenin (canonical) signaling activation in various study populations. There are currently no targetable treatments for BRAF -wildtype ATC and a lack of effective treatment for BRAF V600E ATC. Our aim is to identify whether Wnt inhibitors could be potential therapeutic agents for ATC patients with limited treatment options.
endocrinology & metabolism
What problem does this paper attempt to address?